Eugenia Girda, MD
Gynecologic Oncology · New Brunswick, NJNPI 1497032106
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,135 of the $2,373 with a category attached, or 90.0%. Merck accounts for 91.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $2,170 and has fallen 95.3% since, to $101 in 2024.
Across 4 payments — averaging $593.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Genentech USA, Inc.$102
- Regeneron Healthcare Solutions, Inc.$101
Across 261 payments — averaging $16,126 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2M
- Merck$1.6M
- Astellas Pharma Global Development$175K
- Astrazeneca UK Limited$164K
- Genentech, Inc.$110K
- Exelixis Inc.$107K
- plus $59K from 6 others
What the payments were for
- Consulting fees$2,13590%
- Food & beverage$23810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $2,170 |
| Genentech USA, Inc. | 1 | $102 |
| Regeneron Healthcare Solutions, Inc. | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,373 in reported general payments places this provider in the 70th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 11 | $155,697 |
| Letrozole | 14 | $276 |
| Prochlorperazine Maleate | 20 | $85 |
| Ondansetron Hcl | 15 | $58 |
| Oxycodone Hcl | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in New Brunswick
- Ruth StephensonNew Brunswick$277
- Sara IsaniNew Brunswick$196
- Michael GoldbergNew Brunswick$187
- Sharyn LewinTeaneck$968K
- Scott RichardFlorham Park$84K
- Joyce VarughesePennington$16K
- James BosscherNeptune$13K
- Daniel TobiasMorristown$11K
- Karim ElsahwiNeptune$11K
- William BurkeParamus$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.